(vianews) - shares of poxel (cac 40: poxel.pa) fell by a staggering 15.47% in 5 sessions from €0.77 to €0.65 at 14:05 est on tuesday, after four successive sessions in a row of losses. cac 40 is sliding 0.87% to €7,413.24, following the last session's downward trend.
poxel's last close was €0.66, 76.48% under its 52-week high of €2.82.
about poxel
poxel s.a., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. the company's lead product is twymeeg (imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in japan. it also develops pxl770, an adenosine monophosphate-activated protein kinase enzyme, which is in a phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (nash); pxl065, an earlier stage programs that is in phase 2 for the treatment of nash focusing on chronic and rare metabolic indications. the company has a licensing agreement with enyo pharma s.a.s. for the development of farnesoid x receptor that is in phase 2a study for the treatment of hepatitis b and nash; and deuterx llc for the development of pxl065, a mitochondrial pyruvate carrier inhibitor, which is in a phase i clinical trial for the treatment of nash. poxel s.a. was incorporated in 2009 and is headquartered in lyon, france.
earnings per share
as for profitability, poxel has a trailing twelve months eps of €-1.09.
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -323.36%.moving average
poxel's worth is under its 50-day moving average of €0.70 and way below its 200-day moving average of €1.23.volume
today's last reported volume for poxel is 51856 which is 68.76% below its average volume of 155900.
revenue growth
year-on-year quarterly revenue growth declined by 99.4%, now sitting on 206k for the twelve trailing months.
more news about poxel (poxel.pa).